2016 Fiscal Year Final Research Report
Novel B cell targetting therapies in systemic autoimmune diseases
| Project/Area Number |
26461466
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Collagenous pathology/Allergology
|
|---|
| Research Institution | Saga University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
TASHIRO Satoko
NAGAO Natsumi
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | plasmablast / B細胞 / CD180(RP105) / 自己免疫疾患 / IgG4関連疾患 / SLE / 自己抗体 / 抗体免疫療法 |
|---|
| Outline of Final Research Achievements |
CD180 (RP105) molecule is expressed on B cells. RP105 is associated with B cell function, survival and death. RP105-lacking B cells produce autoantibodies, including anti-ds-DNA antibodies in SLE. Large population of plasmablasts lacking RP105 are found in patients with systemic autoimmune diseases and take part in pathophysiology. We have studied clinical significance of RP105-negative B cells including plasmablasts in various immune-based diseases. We also analyzed the 5 sub-populations of plasmablasts in the various diseases. RP105-negative plasmablasts play crucial roles in systemic autoimmune and immune-based inflammatory disorders. Also, distribution of sub-population and difference of expressed antigens in RP105-lacking plasmablasts may be associated with pathophysiology in individual disorders.
|
| Free Research Field |
医歯薬学
|
